Central-acting angiotensin-converting enzyme (ACE) inhibitors have been reported to prevent cognitive impairment [3,4] and decrease β-amyloid-dependent neurodegeneration [5] in animal models of Alzheimer’s disease. Here, ACE is linked to early-onset autosomal dominant Alzheimer disease.